株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性胆汁性胆管炎(PBC)治療市場: 市場機会分析および将来予測

Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

発行 Coherent Market Insights 商品コード 817596
出版日 ページ情報 英文 143 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
原発性胆汁性胆管炎(PBC)治療市場: 市場機会分析および将来予測 Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
出版日: 2019年03月18日 ページ情報: 英文 143 Pages
概要

当レポートでは、原発性胆汁性胆管炎(PBC)治療の世界市場を調査し、市場の概要、タイプ、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:治療タイプ別
    • 市場スニペット:流通チャネル別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場のダイナミクス、規制、動向分析

  • マーケットダイナミクス
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • 技術の進歩
  • パイプライン分析
  • 疫学
  • 合併と買収
  • 規制シナリオ
  • 政府の取り組み
  • PEST分析

第4章 原発性胆汁性胆管炎(PBC)治療市場:治療タイプ別

  • イントロダクション
  • ウルソデオキシコール酸(UDCA)
  • オベチコール酸 (Ocaliva)

第5章 原発性胆汁性胆管炎(PBC)治療市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 原発性胆汁性胆管炎(PBC)治療市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • 中南米
  • アフリカ
  • 中東

第7章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
    • Novartis AG
    • Bristol-Myers Squibb.
    • NGM Biopharmaceuticals.
    • Lumena Pharmaceuticals, Inc,
    • TARGET PharmaSolutions,
    • Intercept Pharmaceuticals, Inc
    • Teva Pharmaceutical Industries Ltd.
    • Retrophin, Inc.
    • Calliditas Therapeutics AB.
    • GlaxoSmithKline (GSK) pharmaceuticals.
  • アナリストの意見

第8章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years. It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4 known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and environmental factors.

Market Dynamics

Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by the U.S. FDA.

Moreover, in February 2018, U.S.FDA granted orphan drug designation (ODD) to Calliditas Therapeutics AB, specialty pharmaceutical company engaged in development of high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in Stockholm, Sweden, for the treatment of Primary biliary cholangitis (PBC).

Furthermore, key players are engaged in conducting clinical trial to develop treatment for primary biliary cholangitis. For instance, in February 2017, Zydus Cadila received the US Food and Drug Administration (USFDA) approval to initiate a Phase-2 clinical trial of Saroglitazar Magnesium (Mg) in patients with Primary Biliary Cholangitis of the liver.

Key features of the study:

  • This report provides in-depth analysis of the primary biliary cholangitis treatment market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global Primary Biliary Cholangitis Treatment Market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Retrophin, Inc., Calliditas Therapeutics AB, and GlaxoSmithKline (GSK) pharmaceuticals.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global Primary Biliary Cholangitis Treatment Market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for Primary Biliary Cholangitis Treatment Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Primary Biliary Cholangitis Treatment Market, By Treatment Type
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
  • Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Primary Biliary Cholangitis Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Treatment Type:
    • Ursodeoxycholic acid (UDCA)
    • Obeticholic acid (Ocaliva)
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Novartis AG,*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bristol-Myers Squibb.
    • NGM Biopharmaceuticals
    • Lumena Pharmaceuticals, Inc.
    • TARGET PharmaSolutions, Inc
    • Intercept Pharmaceuticals, Inc
    • Teva Pharmaceutical Industries Ltd
    • Retrophin, Inc.
    • Calliditas Therapeutics AB.
    • GlaxoSmithKline (GSK) pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Treatment Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Technology Advancements
  • Pipeline Analysis
  • Epidemiology
  • Merger and Acquisition
  • Regulatory Scenario
  • Government Initiatives
  • PEST Analysis

4. Global Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Ursodeoxycholic acid (UDCA)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Obeticholic acid (Ocaliva)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Primary Biliary Cholangitis Treatment Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Treatment Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • NGM Biopharmaceuticals.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lumena Pharmaceuticals, Inc,
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • TARGET PharmaSolutions,
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Intercept Pharmaceuticals, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Retrophin, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Calliditas Therapeutics AB.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • GlaxoSmithKline (GSK) pharmaceuticals.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top